A Phase 2 interventional study of Pegloticase and Azathioprine in Gout, sponsored by Ampel BioSolutions, LLC. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Ampel BioSolutions, LLC · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 6th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Ampel BioSolutions, LLC is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Ampel BioSolutions, LLC has 1 study filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.
This is an exploratory open-label, multicenter study to evaluate the effectiveness of a 16-week high zone tolerance regimen of pegloticase on response to therapy (serum uric acid \<6 mg/dL) with this drug in adult hyperuricemic patients with gout refractory to conventional therapy.
Eligible subjects will receive 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
Subjects will be monitored for efficacy and safety endpoints through Week 17. Subjects will also have blood drawn for pegloticase levels prior to each dose on Weeks 2, 3, 5, 7, 9, 11, 13,15, and 17. Following Study Week 17, subjects will have an option to continue dosing for an additional 8 weeks.
A subset of subjects will participate in additional pharmacokinetic (PK) assessments.
The study duration, per enrolled patient, will be approximately 26 weeks including a 2-week screening period, a 16-week treatment period (end of treatment [EOT] visit Week 17), and an optional 8-week dosing extension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of defined as:
Currently on dialysis
Additional Exclusion Criteria for Imaging Sub-study Only
Any internal metallic objects such as bullets or shrapnel, as well as most surgical clips, pins, plates, screws, metal sutures, or wire mesh.
Additional Exclusion Criteria for FDG-PET-CT Sub-study Only
Contraindication to FDG
Additional Exclusion Criteria for Pegloticase and AZA Therapy Arm Only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects weighing \<120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
Biological: Pegloticase
Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
Biological: Pegloticase
Subjects weighing \<120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
Biological: Pegloticase
A subset of subjects participating in the Main Study and weighing \<120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
Biological: Pegloticase
A subset of subjects participating in the Main Study and weighing \<120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
Biological: Pegloticase
Subjects weighing \<120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
Biological: Pegloticase · Drug: Azathioprine
Pegloticase, IV
Also known as: Krystexxa
Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
Also known as: Imuran
Normalization of serum uric acid (SUA) in subjects receiving a tolerizing regimen of pegloticase
Determine response rate; the last 3 consecutive levels of SUA must be \<6 mg/dL
Time frame: Week 17
Normalization of serum uric acid (SUA) in subjects receiving pegloticase and azathioprine (AZA) immunosuppressive therapy
Determine response rate; the last 3 consecutive levels of SUA must be \<6 mg/dL
Time frame: Week 25
Change from baseline in SUA to end of Treatment
Change from baseline
Time frame: Baseline and Week 17
Change from baseline in SUA to end of Treatment
Change from baseline - AZA arm
Time frame: Baseline and Week 25
Proportion of subjects with SUA <5 mg/dL
Proportion of subjects
Time frame: Week 17
Proportion of subjects with SUA <5 mg/dL
Proportion of subjects - AZA arm
Time frame: Week 25
Proportion of subjects with SUA <2 mg/dL
Proportion of subjects
Time frame: Week 17
Proportion of subjects with SUA <2 mg/dL
Proportion of subjects - AZA arm
Time frame: Week 25
Infusion reactions (IRs) and anaphylaxis
Incidence - AZA arm
Time frame: Week 17
Infusion reactions (IRs) and anaphylaxis
Incidence
Time frame: Week 25
Incidence of anti-pegloticase antibodies
Anti-pegloticase antibodies
Time frame: Week 17
Incidence of anti-pegloticase antibodies
Anti-pegloticase antibodies - AZA arm
Time frame: Week 25
Mean titer of anti-pegloticase antibodies
Anti-pegloticase antibodies
Time frame: Week 17
Mean titer of anti-pegloticase antibodies
Anti-pegloticase antibodies AZA arm
Time frame: Week 25
Incidence of gout flares, adverse events (AEs), serious AEs (SAEs), and early terminations due to AEs
Incidence
Time frame: Week 17
Incidence of gout flares, adverse events (AEs), serious AEs (SAEs), and early terminations due to AEs
Incidence - AZA arm
Time frame: Week 25
Relationship in change from baseline in SUA from baseline with rate of infusion reactions
Correlation between change in SUA and infusion reactions
Time frame: Baseline to Week 17
Relationship in change from baseline in SUA from baseline with rate of infusion reactions
Correlation between change in SUA and infusion reactions - AZA arm
Time frame: Baseline to Week 25
Compare trough pegloticase levels
Descriptive statistics
Time frame: Week 17
Compare trough AZA levels
Descriptive statistics
Time frame: Week 25
Ability of imaging to monitor treatment response
To compare the ability of dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to monitor treatment response, in a subset of subjects weighing \< 120 kg
Time frame: Baseline and Week 17
Evaluate change from baseline carotid and aortic (chest) atherosclerosis
Change from baseline as measured by fluorodeoxyglucose-positron emission tomography (FDG-PET-CT), in a subset of subjects weighing \< 120 kg
Time frame: Baseline and Week 17
Cmax of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
Tmax of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
AUC of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
Terminal phase half-life of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
CL of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
Vss of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
Accumulation Ratio (AR) of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
PK parameter
Time frame: Up to Week 17
Ran from Dec 2015 to primary completion in Apr 2020, 52 months.
Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's 52 months is above that.
Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegloticase
Ampel BioSolutions, LLC